摘要
目的探讨吸入沙美特罗替卡松粉剂对慢性阻塞性肺疾病（chronic obstructive pulmonarydisease，COPD）稳定期患者血清肺表面活性物质相关蛋白D（surfactantassociated proteinD，SP—D）浓度的影响。方法选择Ⅲ级及Ⅳ级稳定期COPD患者84例，随机分为沙美特罗（50tLg）和沙美特罗替卡松粉剂（50μg／500pg）两组，每组42例，每例患者均吸入2次／日，每次1吸，疗程12周。收集治疗前后血清标本各一份，采用ELISA法检测患者血清SPD浓度。结果治疗前后平均血清SP—D浓度吸入沙美特罗替卡松粉剂治疗组患者分别为（148．2±65．7）μg／L和（89．2±53．2）μg／L，治疗前后血清平均SPD水平差异有统计学意义（P〈0．05）。单纯吸入沙美特罗粉剂组治疗前后患者血清SP—D浓度分别为（143．5±69．1）μg／L和（136．7±59．5）Mg／L，治疗前后血清平均SP—D水平差异无统计学意义（P〉0．05）。结论稳定期COPD患者吸人沙美特罗替卡松粉剂治疗后血清SPD浓度比治疗前降低，血清SPD浓度检测可能成为一个潜在的COPD治疗的生物学检测指标。
Objective To determine the effect of inhaled salmeterol/fluticasone on serum surfactant protein D（SP-D） in patients with stable chronic obstructive pulmonary disease （COPD）. Methods 84 COPD patients were randomly divided into two groups;group 1 （ n = 42） were treated with salmeterol （50 μg） alone, and group 2 （ n =42） with salmeterol/fluticasone （50 μg/500 μg）, each patient inhaled twice daily for 12 weeks. Serum samples were taken at baseline and after 12 weeks of treatment. The levels of serum SP-Dwere detected using ELISA. Results The average serum SP-D for patients were significantly decreased from （148.2±65.7） μg/L to （89.2±53.2） μg/L （P d0.05） in patients who inhaled salmeterol/fluticasone. The average serum SP-D for patients who inhaled salmeterol alone was （143.5± 69.1） μg/L and （136.7±59.5）μg/L at baseline and after inhaled salmeterol were not significant （P 〉 0.05 ）. Conclusions The serum SP-D in patients with stable COPD decreases significantly after treatment with inhaled salmeterol/fluticasone, which may be a potential diagnostic biomarker for COPD treatment.
出处
《国际呼吸杂志》
2012年第18期1396-1398,共3页
International Journal of Respiration
